Fiaz Zaman, MD
Ophthalmology · Houston, TXNPI 1073508164
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AbbVie at 50.7% of the total. Reporting peaked in 2019 at $56,110 and has fallen 96.7% since, to $1,831 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $204.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$58K
- Aerie Pharmaceuticals, Inc.$47K
- NEW World Medical,inc.$2K
- Alcon$2K
- Glaukos Corporation$1K
- Ivantis, Inc$839
- plus $4K from 20 others
Across 251 payments — averaging $3565.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$581K
- Ocular Therapeutix, Inc.$170K
- AbbVie$62K
- Alcon Research LLC$41K
- Aerie Pharmaceuticals, Inc.$40K
- Ivantis, Inc$2K
What the payments were for
- Consulting fees$48,33942%
- Speaking & faculty fees$41,12236%
- Travel & lodging$12,70911%
- Food & beverage$13,17711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 246 | $58,440 |
| Aerie Pharmaceuticals, Inc. | 62 | $46,986 |
| NEW World Medical,inc. | 7 | $2,072 |
| Alcon | 51 | $1,861 |
| Glaukos Corporation | 25 | $1,357 |
| Ivantis, Inc | 6 | $839 |
| Sun Pharmaceutical Industries Inc. | 28 | $590 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $448 |
| Novartis | 29 | $403 |
| Tarsus Pharmaceuticals, Inc. | 12 | $320 |
| Bausch & Lomb Americas Inc. | 13 | $292 |
| Kala Pharmaceuticals, Inc. | 16 | $261 |
| Carl Zeiss Meditec USA, Inc. | 5 | $231 |
| Harrow Eye, LLC | 11 | $214 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $152 |
| Rxsight Inc | 3 | $150 |
| Eyevance Pharmaceuticals LLC | 5 | $106 |
| Oyster Point Pharma, Inc. | 4 | $106 |
| Carl Zeiss Meditec, Inc. | 2 | $91 |
| Ocular Therapeutix, Inc. | 4 | $89 |
| Thea Pharma Inc. | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 4 | $80 |
| Sight Sciences, Inc. | 3 | $66 |
| Iridex Corporation | 1 | $59 |
| Dompe US, Inc. | 1 | $29 |
| Akorn, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$46,339
- Rhopressa$34,822
- DURYSTA$15,808
- LUMIGAN$13,034
- COMBIGAN$3,800
- XEN GLAUCOMA TREATMENT SYSTEM$3,395
- Ahmed Glaucoma Valve$1,974
- Kahook Dual Blade$1,974
- RESTASIS MULTIDOSE$1,039
- XEN$625
- Hydrus$500
- RESTASIS$400
- Hydrus Microstent$382
- KXL System$247
- Photrexa$247
- iDoseTR$173
- Clareon$150
- PanOptix$150
- ReSTOR$141
- LenSx$131
How this compares
$115,346 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 1,633 | $933,673 |
| CombiganBrimonidine Tartrate/Timolol | 844 | $401,763 |
| RestasisCyclosporine | 173 | $227,032 |
| RhopressaNetarsudil Mesylate | 369 | $198,297 |
| RocklatanNetarsudil Mesylat/Latanoprost | 255 | $152,897 |
| XiidraLifitegrast | 68 | $72,213 |
| VyzultaLatanoprostene Bunod | 113 | $57,679 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 299 | $52,569 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 112 | $35,257 |
| Alphagan PBrimonidine Tartrate | 86 | $35,206 |
| Travoprost | 223 | $29,375 |
| TyrvayaVarenicline Tartrate | 24 | $28,167 |
| Cyclosporine | 29 | $25,159 |
| Lotemax SmLoteprednol Etabonate | 101 | $25,054 |
| Latanoprost | 2,052 | $22,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $58,440 | $1,597,6752,736 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $46,986 | $351,194624 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $292 | $129,892181 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $448 | $46,450165 claims |
| AlconSimbrinza, Azopt | $1,861 | $40,901125 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $106 | $28,16724 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $320 | $20,54812 claims |
| NovartisTravatan Z | $403 | $14,62028 claims |
| Harrow Eye, LLCVevye | $214 | $12,96312 claims |
| Akorn, Inc.Zioptan | $23 | $10,48724 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $590 | $7,36813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.